Deprescribing: The Highest-Impact Clinical Service Pharmacists Can Deliver

Geriatrics / Polypharmacy 1 source · Updated Aug 4, 2026

Evidence-based frameworks for pharmacist-led deprescribing of PPIs, benzodiazepines, opioids, anticholinergics, and antihyperglycemics.

Bottom Line

Deprescribing consistently reduces medication burden without increasing adverse outcomes, and pharmacists are the best-positioned clinicians to lead systematic deprescribing programs across PPIs, benzodiazepines, opioids, anticholinergics, and antihyperglycemics.

State of Play

Deprescribing has evolved from an informal practice to a structured, evidence-based clinical service. Multiple RCTs and systematic reviews now support pharmacist-led deprescribing interventions across the five highest-impact drug classes.

Evidence at a Glance

Source	Key finding	Grade / Verdict
Deprescribing: The Highest-Impact Clinical Service Pharmacists Can Deliver Study · PharmD Signal Reference Card	—

reference-card

🎓

Synthesized and reviewed by a licensed pharmacist

Each topic review is built from our published deep analyses and checked for clinical accuracy before it goes live.

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.

Thanks for the feedback!

← Back to Hot Topics